Education
About Us
Working with TipRanks
Follow Us
GT Biopharma (GTBP)
NASDAQ:GTBP
GTBP Stock Chart & Stats
$0.73
-$0.23(-8.01%)
At close: 4:00 PM EST
$0.73
-$0.23(-8.01%)
Day’s Range― - ―
52-Week Range$0.40 - $3.85
Previous CloseN/A
Volume15.05K
Average Volume (3M)1.63M
Market Cap
$14.81M
Enterprise Value-$1.83M
Total Cash (Recent Filing)$6.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.45
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding31,553,892
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$3.00Price Target Upside310.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory/Clinical MilestoneFDA IND clearance for GTB-5550 advances a third TriKE candidate into clinical testing, broadening the company's biologics pipeline. Clinic entry materially de-risks that program, enables generation of human safety/early efficacy data, and validates the TriKE platform for solid tumor indications over the medium term.
Cash RunwayAn estimated proforma cash balance of ~$9M gives GT Biopharma runway into Q4 2026, supporting initiation of the planned Phase 1 for GTB-5550 and continued GTB-3650 dosing. This funding window reduces immediate financing pressure and allows execution of near-term clinical milestones that are central to program advancement.
Low LeverageA very low debt profile minimizes interest obligations and insolvency risk, preserving financial flexibility. For a clinical-stage biotech, low leverage allows the company to prioritize R&D spending and pursue equity, partnerships, or milestone-based financings without fixed repayment burdens that could constrain long-term project execution.
Bears Say
Cash BurnSustained negative operating and free cash flow (~-$12.9M TTM) is a structural constraint for a pre-commercial biotech. With ongoing burn and no product revenue, GT Biopharma will remain dependent on external financing or partnerships to fund trials, creating recurring dilution risk and operational vulnerability if markets tighten.
No Revenue / Heavy LossesThe company is a pre-commercial R&D organization with no revenue and persistent heavy losses, which means long-term viability depends on successful clinical outcomes and future commercialization. Absent successful trials or partner support, the lack of revenue makes sustainable operations contingent on repeated financing rounds.
Eroding Equity BaseMaterial decline in shareholders' equity and a prior negative equity reading reflect cumulative operating losses that have eroded capital cushions. A weakened equity base reduces the company's ability to absorb trial setbacks and increases the likelihood of dilutive financings to restore balance-sheet strength, raising governance and solvency risk.
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.40 and its highest was $3.85 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $14.81M.
When is GT Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GT Biopharma’s earnings last quarter?
Currently, no data Available
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Undervalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 31,553,892 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
GTBP Stock 12 Month Forecast
Average Price Target
$3.00
▲(310.96% Upside)
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
3.21%
Insiders
0.10% Mutual Funds
0.52% Other Institutional Investors
96.15% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---